Effect of treatment with quetiapine on mismatch negativity potentials in childhood and adolescent schizophrenia

Abstract

Objective To study the mismatch negativity potentials effects of quetipine treatment on childhood and adolescent schizophrenia. Methods 23 patients (among 6'15 years old) met with DSM-IV for schizophrenia criteria were enrolled as research group and 23 healthy children and adolescents were selected as normal control group that performed the frequency and duration deviant MMN task. MMN latency and amplitude at Fz electrodes were obtained. The research group was treated with quetipine for 8 weeks and assessed with PANSS. MMN amplitudes and latencies of all groups were compared with each other respectively. Result Quetipine decreased all PANSS scales(P <0.05). Patients showed smaller mean amplitudes of frequency and duration MMN[(1.57 ±0.9)μV,(1.53±0.8)μV respectively] than controls[(2.01 ±0.4)μV,(2.00±0.86)μV respectively](P <0.05). A two-way repeated measures ANOVA with MMN type (frequency vs. Duration) and session as between-subject factors revealed no significant MMN type or MMN type ×session interaction for MMN amplitudes (for MMN type:F =0.704,dF =1,P =0.403; for MMN type ×session:F =0.299,dF =2,P =0.796) and significant effects of session(F =3.576,dF =2,P =0.031). A multiple comparisons by LSD tests demonstrated significant differences between MMN amplitudes at after 8-week treatment and at baseline (P =0.025) or at 4-week treatment (P =0.020) and no significant differences between MMN amplitudes at after 4-week treatment and at baseline (P =0.935). MMN amplitudes at 8-week treatment[(1.94 ±0.5)μV,(1.88±0.7)μV respectively] are higher than at 4-week treatment[(1.65 ±0.8)μV,(1.42±0.7)μV respectively]and at baseline(P <0.05).Conclusions It presents cognitive dysfunction in childhood and adolescent schizophrenia.In neuroelectrophysical aspect,MMN offers objective evidence that treatment with the Quetiapine improves cognitive function in childhood and adolescent schizophrenia. Key words: Childhood and adolescent; Schizophrenia; MMN; Quetiapine; Cognitive function